JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265084

Human PKDCC (VLK) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PKDCC KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 32 bp deletion in exon 1.

View Alternative Names

FLJ18197, Hypothetical protein BC007901, Hypothetical protein LOC91461, MGC125960, PKDCC_HUMAN, Protein kinase domain containing cytoplasmic, Protein kinase domain containing, cytoplasmic homolog (mouse), Protein kinase domain-containing protein, cytoplasmic, Protein kinase-like protein SgK493, SGK493, Sugen kinase 493, Vertebrate lonesome kinase

1 Images
Sanger Sequencing - Human PKDCC (VLK) knockout HeLa cell line (AB265084)
  • Sanger seq

Unknown

Sanger Sequencing - Human PKDCC (VLK) knockout HeLa cell line (AB265084)

Homozygous : 32 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 32 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265084-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265084 Human PKDCC (VLK) knockout HeLa cell line", "number":"AB265084-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265084-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265084 Human PKDCC (VLK) knockout HeLa cell line", "number":"AB265084-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PKDCC
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VLK also known as V-set and transmembrane domain-containing protein E is a serine/threonine kinase with a molecular mass of approximately 54 kDa. It localizes mainly in the Golgi apparatus. Scientists detect VLK expression across various tissues including the heart testis and liver. This kinase executes post-translational modifications by phosphorylating intracellular proteins which can modulate their functions and interactions.
Biological function summary

VLK kinase activity impacts protein folding and trafficking within the Golgi apparatus. VLK associates with protein complexes involved in secretory pathways assisting cellular functions like protein secretion and cell surface expression. Research indicates that it contributes significantly to maintaining cellular homeostasis by ensuring proper protein maturation.

Pathways

VLK plays a role in the secretory pathway which is essential for the transport and delivery of proteins and lipids throughout the cell. It shows interactions with proteins like ABCD3 and VCP that are pivotal in vesicular transport and protein quality control. VLK also participates in the RAS signaling pathway linking it to cell growth and differentiation by affecting downstream targets.

Recent studies highlight VLK's involvement with neurodegenerative diseases and cancer. Altered VLK activity correlates with conditions such as Alzheimer's disease where phosphorylation imbalances disrupt neuron function. In cancer VLK is overexpressed leading to misregulated cell proliferation. Connections to proteins like tau and LATS1 further demonstrate VLK's relevance in these diseases influencing both progression and therapeutic targeting.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com